
Mission
The Clinical Development Quality Manager (CDQM) is responsible for ensuring quality oversight across clinical development activities and supporting the maintenance of GCP compliance. This role supports stakeholders in vendor qualification, study risk management, quality oversight, team training compliance, and coaching as needed. Responsibilities include monitoring Key Quality Indicators (KQIs), analyzing trends in quality events, ensuring protocol adherence and providing support for quality events, audits, and corrective and preventive actions (CAPAs). The CDQM ensures proactive identification and mitigation of risks to maintain the integrity of clinical trial data and protect patient safety.
Main responsibilities
GCP Support and Oversight :
Vendor Qualification and Oversight :
Risk Management :
Audit and Inspection Readiness :
Quality Events and Deviations Management :
Team Training and Compliance Oversight :
Continuous Improvement :
Requirements
Profile
Benefits
What we Offer
· Being part of a company where innovation, collaboration, and impact aren’t just values — they’re how we work every day
· Partner with teams across disciplines, at the forefront of oncology and anti-infective development
· An inclusive and respectful workplace — proud to be Equal-Pay certified
· Grow in a culture that values people, purpose, and performance
· A chance to grow, share, and shape the future of healthcare
What to Expect in the Recruitment Process:
If your application is selected, you’ll be invited to interviews with Talent Acquisition and the Hiring Manager via Teams, followed by a panel interview and reference checks. Communication is handled via Workable—check your spam folder for emails from *@outbound.workable.com.
We do not accept unsolicited applications from agencies or recruiters.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe.
Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections.
Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®
If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!